Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study

Table 4 The results of the two-piecewise linear regression model

AGR	No. of participants	Hazard ratio (95% CIs)	p-value
Fitting model by standard linear regression	196	0.60 (0.26, 1.36)	0.2191
Fitting model by two-piecewise linear regression
≤ 1.24	41	13.05 (0.52, 327.64)	0.1183
> 1.24	155	0.20 (0.07, 0.57)	0.0025
p for log-likelihood ratio test			0.0240

Adjusted for: Age; Gender; Never smoker; Hypertension; ALK rearrangement; EGFR mutation; Histology; Tumor stage; ECOG PS score; Number of metastases; Number of previous treatment lines; Number of previous chemotherapy lines; Previous targeted therapy; Previous radiotherapy; Previous immunotherapy; Anlotinib monotherapy; Leukocyte; Neutrophil; Lymphocyte; Platelets. Restricted cubic spline was applied

ISSN: 1471-2466